tiprankstipranks
Advertisement
Advertisement

ACAD Stock Latest News

Acadia Shareholders Approve Directors, Executive Pay and Equity Plan
Company AnnouncementsAcadia Shareholders Approve Directors, Executive Pay and Equity Plan
19d ago
8K
ACAD
Acadia Pharmaceuticals price target lowered to $32 from $33 at Citi
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $32 from $33 at Citi
1M ago
ACAD
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call
PremiumCompany Announcements
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call
1M ago
ACAD
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained
PremiumRatings
ACADIA: Buy Rating Reiterated on Durable Commercial Strength and Pipeline Catalysts; $37 Price Target Maintained
1M ago
ACAD
ACADIA: Buy Rating Reiterated on Nuplazid/Daybue Upside and Remlifanserin Optionality; $32 DCF-Based Price Target Maintained
PremiumRatings
ACADIA: Buy Rating Reiterated on Nuplazid/Daybue Upside and Remlifanserin Optionality; $32 DCF-Based Price Target Maintained
1M ago
ACAD
Acadia Pharmaceuticals reports Q1 EPS 2c, consensus 8c
PremiumThe FlyAcadia Pharmaceuticals reports Q1 EPS 2c, consensus 8c
1M ago
ACAD
Acadia Pharmaceuticals backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B
Premium
The Fly
Acadia Pharmaceuticals backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B
1M ago
ACAD
Is ACAD a Buy, Before Earnings?
Premium
Pre-Earnings
Is ACAD a Buy, Before Earnings?
1M ago
ACAD
Acadia Announces Planned Retirement of Head of R&D
PremiumCompany Announcements
Acadia Announces Planned Retirement of Head of R&D
2M ago
8K
ACAD
Acadia Pharmaceuticals price target lowered to $29 from $30 at RBC Capital
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $29 from $30 at RBC Capital
2M ago
ACAD
Acadia Pharmaceuticals announces Daybue Stix available in U.S.
PremiumThe Fly
Acadia Pharmaceuticals announces Daybue Stix available in U.S.
2M ago
ACAD
Arm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Arm upgraded, Mondelez downgraded: Wall Street’s top analyst calls
3M ago
GM
ARE
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
PremiumThe FlyAcadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
3M ago
ACAD
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofA
Premium
The Fly
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofA
3M ago
ACAD
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
Premium
Company Announcements
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee
3M ago
8K
ACAD
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
PremiumThe Fly
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
4M ago
ACAD
Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
PremiumThe Fly
Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
4M ago
ACAD
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
PremiumRatings
Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
4M ago
ACAD
ACADIA Pharmaceuticals Charts Growth Path After Record Year
PremiumCompany Announcements
ACADIA Pharmaceuticals Charts Growth Path After Record Year
4M ago
ACAD
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
PremiumThe FlyAcadia Pharmaceuticals price target lowered to $33 from $36 at Citi
4M ago
ACAD
Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
Premium
The Fly
Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
4M ago
ACAD
Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
Premium
The Fly
Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
4M ago
ACAD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >